COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation of Orally Administered SAR439859 in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03816839
Recruitment Status : Active, not recruiting
First Posted : January 25, 2019
Last Update Posted : October 8, 2020
Information provided by (Responsible Party):

Brief Summary:

Primary Objective:

To assess the incidence rate of dose-limiting toxicity and to confirm the recommended dose as well as the maximum tolerated dose of SAR439859 administered as monotherapy to Japanese postmenopausal women with estrogen receptor positive and human epidermal growth factor receptor 2-negative advanced breast cancer.

Secondary Objective:

  • To characterize the overall safety profile of SAR439859 administered as monotherapy.
  • To characterize the pharmacokinetic profile of SAR439859 administered as monotherapy.
  • To evaluate the antitumor activity of SAR439859 administered as monotherapy and the clinical benefit rate (complete response, partial response and stable disease ≥ 24 weeks).

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: SAR439859 Phase 1

Detailed Description:
The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (28 days) of study treatment, and an End of Treatment (EOT) visit at least 30 days (or until the participant receives another anticancer therapy, whichever is earlier) following the last administration of study treatment. Study treatment may continue until precluded by unacceptable toxicity, disease progression, or upon participant's request.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study for the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy in Japanese Postmenopausal Women With Estrogen Receptor-Positive And Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer (AMEERA-2)
Actual Study Start Date : March 25, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: SAR439859
administered orally once daily or twice daily as monotherapy in fasted or fed state
Drug: SAR439859

Pharmaceutical form: Capsules

Route of administration: Oral

Primary Outcome Measures :
  1. Investigational medicinal product (IMP)-related dose limiting toxicities (DLTs) [ Time Frame: Day 1 to Day 28 ]
    Incidence rate of study treatment-related DLTs at Cycle 1

Secondary Outcome Measures :
  1. Safety: Adverse Events (AEs) [ Time Frame: Up to 30 days after administration of study treatment ]
    Number of adverse events related to study therapy

  2. Assessment of Pharmacokinetic parameter of SAR439859: tlag [ Time Frame: Day 1 and Day 22 of Cycle 1 (28 days) ]
    Lag time, interval between administration time and the sampling time preceding the first concentration above the lower limit of quantification

  3. Assessment of Pharmacokinetic parameter of SAR439859: tmax [ Time Frame: Day 1 and Day 22 of Cycle 1 (28 days) ]
    First time to reach Cmax

  4. Assessment of Pharmacokinetic parameter of SAR439859: Cmax [ Time Frame: Day 1 and Day 22 of Cycle 1 (28 days) ]
    Maximum concentration observed

  5. Assessment of Pharmacokinetic parameter of SAR439859: AUC0-24h or AUC0-10h and/or AUC0-12h [ Time Frame: Day 1 and Day 22 of Cycle 1 (28 days) ]
    Area under the plasma concentration versus time curve over the dosing interval (24 hours, 10 hours or 12 hours)

  6. Assessment of Pharmacokinetic parameter of SAR439859: Ctrough [ Time Frame: Day 1, Day 8, Day 15 and Day 22 of Cycle 1 (28 days) and Day 1 of Cycle 2 ]
    Plasma concentration observed just before treatment administration during repeated dosing

  7. Assessment of antitumor activity: Objective response rate (ORR) [ Time Frame: 64 weeks ]
    Objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

  8. Assessment of antitumor activity: Clinical benefit rate (CBR) [ Time Frame: 64 weeks ]
    Clinical benefit rate is (CR [complete response] +PR [partial response] +SD [stable disease] ≥24 weeks) as per RECIST 1.1

  9. Assessment of antitumor activity: Duration of response [ Time Frame: 64 weeks ]
    Response duration defined as the time from initial response to the first documented tumor progression

  10. Assessment of antitumor activity: Non-progression rate [ Time Frame: 64 weeks ]
    Non-progression rate at 24 weeks (percentage of participants without progression at 24 weeks)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria :

  • Participants must be postmenopausal women.
  • Breast adenocarcinoma patients with locally advanced not amenable to radiation or surgery, inoperable and/or metastatic disease.
  • Either the primary or any metastatic site must be positive for estrogen receptor (ER) (>1% staining by immunohistochemistry).
  • Either the primary tumor or any metastatic site must be human epidermal growth factor receptor 2 non-overexpressing.
  • Patients with at least 6 months of prior endocrine therapy.

Exclusion criteria:

  • Eastern Cooperative Oncology Group Performance Status (ECOG) ≥2.
  • Significant concomitant illness that would adversely affect participation in the study.
  • Patients with a life expectancy less than 3 months.
  • Patient not suitable for participation, whatever the reason.
  • Major surgery within 4 weeks prior to first study treatment administration.
  • Treatment with strong and moderate cytochrome P450 3A inhibitors/inducers.
  • Patients with known endometrial disorders, uterine bleeding or ovarian cysts.
  • Treatment with anticancer less than 2 weeks before first study treatment.
  • Prior treatment with selective estrogen receptor down (SERD)-regulator (except fulvestrant for which a washout of at least 6 weeks is required).
  • Inadequate hematological function.
  • Inadequate renal function with serum creatinine ≥1.5 x upper limit of normal (ULN).
  • Liver function: aspartate aminotransferase >3 x ULN, or alanine aminotransferase >3 x ULN. Total bilirubin >1.5 x ULN.
  • Non-resolution of any prior treatment related toxicity to <Grade 2, except for alopecia

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03816839

Layout table for location information
Investigational Site Number 3920002
Chuo-Ku, Japan
Investigational Site Number 3920001
Kashiwa-Shi, Japan
Investigational Site Number 3920003
Nagoya-Shi, Japan
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT03816839    
Other Study ID Numbers: TED15954
U1111-1217-2758 ( Other Identifier: UTN )
First Posted: January 25, 2019    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases